Review

wsx1 (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems wsx1
Quantification of biomarkers.

Wsx1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wsx1/product/R&D Systems
Average 93 stars, based on 6 article reviews

wsx1 - by Bioz Stars, 2026-06

93/100 stars

Images

1) Product Images from "Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner"

Article Title: Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner

Journal: Frontiers in Immunology

doi: 10.3389/fimmu.2025.1550699

Figure Legend Snippet: Quantification of biomarkers.

Techniques Used:

Detection of WSX and gp130 on M2 macrophages using FACS. The surface expression of WSX1 and gp130 on M2 macrophages was assessed by flow cytometry as described in the Materials and Methods. (A) The left and right panels show WSX1 and gp130 (CD130) staining, respectively. The staining pattern of isotype control antibodies is shown in gray line, and black indicates the protein of interest. The x-axis and y-axis show fluorescence intensity and cell counts, respectively. The percentages in the panels indicate the percentage of cells expressing WSX1 or gp130 in the samples. Data are representative of three independent experiments with similar outcomes. (B) Flow cytometric analysis of M2 macrophages showing the expression of WSX1 and gp130 (CD130) from one donor M2 macrophages. (C) FACS analysis for WSX1 and gp130 expression on M2 cells was performed using three independent donor cells. Results indicated means ± SE (n = 3). FACS, fluorescence-activated cell sorting.

Figure Legend Snippet: Detection of WSX and gp130 on M2 macrophages using FACS. The surface expression of WSX1 and gp130 on M2 macrophages was assessed by flow cytometry as described in the Materials and Methods. (A) The left and right panels show WSX1 and gp130 (CD130) staining, respectively. The staining pattern of isotype control antibodies is shown in gray line, and black indicates the protein of interest. The x-axis and y-axis show fluorescence intensity and cell counts, respectively. The percentages in the panels indicate the percentage of cells expressing WSX1 or gp130 in the samples. Data are representative of three independent experiments with similar outcomes. (B) Flow cytometric analysis of M2 macrophages showing the expression of WSX1 and gp130 (CD130) from one donor M2 macrophages. (C) FACS analysis for WSX1 and gp130 expression on M2 cells was performed using three independent donor cells. Results indicated means ± SE (n = 3). FACS, fluorescence-activated cell sorting.

Techniques Used: Expressing, Flow Cytometry, Staining, Control, Fluorescence, FACS

Image Search Results

Journal: Frontiers in Immunology

doi: 10.3389/fimmu.2025.1550699

Figure Lengend Snippet: Quantification of biomarkers.

Article Snippet: The following antibodies and their respective fluorochrome were used: CD38 (Fluorochrome PE-Cy7; Cat. # 560677, BD Biosciences, Franklin Lakes, NJ, USA), isotype control (Fluorochrome PE-Cy7; Cat. # 557872, BD Biosciences), CD130/GP130 (Fluorochrome AF647, Cat. # 564151, BD Biosciences), isotype control (Fluorochrome AF647, Cat. # 557714, BD Biosciences), WSX1 (Fluorochrome PE; Cat. # FAB14791PO2, R&D Systems), and isotype control (Fluorochrome PE; Cat. # IC0041P, R&D Systems).

Techniques:

Journal: Frontiers in Immunology

doi: 10.3389/fimmu.2025.1550699

Figure Lengend Snippet: Detection of WSX and gp130 on M2 macrophages using FACS. The surface expression of WSX1 and gp130 on M2 macrophages was assessed by flow cytometry as described in the Materials and Methods. (A) The left and right panels show WSX1 and gp130 (CD130) staining, respectively. The staining pattern of isotype control antibodies is shown in gray line, and black indicates the protein of interest. The x-axis and y-axis show fluorescence intensity and cell counts, respectively. The percentages in the panels indicate the percentage of cells expressing WSX1 or gp130 in the samples. Data are representative of three independent experiments with similar outcomes. (B) Flow cytometric analysis of M2 macrophages showing the expression of WSX1 and gp130 (CD130) from one donor M2 macrophages. (C) FACS analysis for WSX1 and gp130 expression on M2 cells was performed using three independent donor cells. Results indicated means ± SE (n = 3). FACS, fluorescence-activated cell sorting.

Techniques: Expressing, Flow Cytometry, Staining, Control, Fluorescence, FACS

a Immunohistochemical (IHC) staining of WSX1 in a human normal tissue microarray (TMA, FDA662a). The images shown are representatives for results of 2 individuals. b IHC staining of WSX1 in HCC TMAs (BC03116a and HLiv-HCC180Sur-03), including human normal liver tissue ( n = 17), NAT ( n = 103, P < 0.0001 compared to normal liver tissue), and HCC ( n = 130, P < 0.0001 compared to both normal liver tissue and NAT) samples. Statistical analysis results are based on quantification of the percentage of WSX1 + area in each TMA tissue core. c Comparisons of the overall survival of HCC patients between low ( n = 47) and high WSX1 expression group ( n = 43, P = 0.0034). Forty HCC patients in TMA BC03116a were excluded due to lack of survival data. d WSX1 expression levels among different tumor pathological grades in HCC patients, including NAT ( n = 103), grade I ( n = 21), grade II ( n = 73, P = 0.0321 compared to grade I) and grade III ( n = 34, P < 0.0001 compared to grade I and P = 0.0123 compared to gradeII). Quantification and statistical analysis results are shown on the right. Scale bars, 50 μm. Quantitative data are presented as mean ± SD. One-way ANOVA was used to calculate the P values. Tukey-Kramer multiple comparison test was used for pairwise comparisons in the ANOVA analysis. The survival curves were analyzed by the Kaplan–Meier method, and the log-rank test was used to compare overall survival between groups. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, **** P < 0.0001. HCC hepatocellular carcinoma, NAT normal tumor-adjacent liver tissue. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

doi: 10.1038/s41467-021-23864-9

Figure Lengend Snippet: a Immunohistochemical (IHC) staining of WSX1 in a human normal tissue microarray (TMA, FDA662a). The images shown are representatives for results of 2 individuals. b IHC staining of WSX1 in HCC TMAs (BC03116a and HLiv-HCC180Sur-03), including human normal liver tissue ( n = 17), NAT ( n = 103, P < 0.0001 compared to normal liver tissue), and HCC ( n = 130, P < 0.0001 compared to both normal liver tissue and NAT) samples. Statistical analysis results are based on quantification of the percentage of WSX1 + area in each TMA tissue core. c Comparisons of the overall survival of HCC patients between low ( n = 47) and high WSX1 expression group ( n = 43, P = 0.0034). Forty HCC patients in TMA BC03116a were excluded due to lack of survival data. d WSX1 expression levels among different tumor pathological grades in HCC patients, including NAT ( n = 103), grade I ( n = 21), grade II ( n = 73, P = 0.0321 compared to grade I) and grade III ( n = 34, P < 0.0001 compared to grade I and P = 0.0123 compared to gradeII). Quantification and statistical analysis results are shown on the right. Scale bars, 50 μm. Quantitative data are presented as mean ± SD. One-way ANOVA was used to calculate the P values. Tukey-Kramer multiple comparison test was used for pairwise comparisons in the ANOVA analysis. The survival curves were analyzed by the Kaplan–Meier method, and the log-rank test was used to compare overall survival between groups. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, **** P < 0.0001. HCC hepatocellular carcinoma, NAT normal tumor-adjacent liver tissue. Source data are provided as a Source Data file.

Article Snippet: PerCP/Cyanine5.5 anti-mouse CD3 (BioLegend 100328), V450 anti-mouse CD8a (Tonbo 75-0081), FITC anti-mouse CD4 (BioLegend 100405), V450 anti-mouse NK1.1 (BD biosciences 560524), PE/Cy7 anti-mouse PD-1 (BioLegend 109109), PE anti-mouse CTLA-4 (BioLegend 106306), PE/Cy7 anti-mouse LAG-3 (BioLegend 125225), PE anti-mouse Tim3 (BioLegend 134009), PE anti-mouse granzyme B (ebioscience 12-8898-80), PE anti-mouse Ki67 (BioLegend 652404), PE anti-mouse perforin (ebioscience 12-9392-82), PE anti-human CD3 (BioLegend 300308), PE/Cy7 anti-human PD-1 (BioLegend 367414), APC anti-mouse TOX (Miltenyi Biotec 130-118-335), APC anti-mouse IFN-γ (ebioscience 17-7311-82), PE anti-mouse IL-2 (BioLegend 503808), PE anti-human WSX1 (R&D FAB14791P), and HRP anti-human/mouse GAPDH (Proteintech HRP-6000).

Techniques: Immunohistochemical staining, Immunohistochemistry, Microarray, Expressing, Comparison

a (Top) Summary of NRAS/AKT oncogene-derived spontaneous HCC mouse model in FVB/NJ mice ( n = 8). Arrowheads represent hydrodynamic injection of WSX1 every week. (Bottom) Representative images of entire mouse livers in the oncogene and oncogene + WSX1 groups. b Comparisons of hematoxylin and eosin (H&E) histology. c Comparisons of percentage of liver area containing preneoplastic/tumor lesions based on H&E results ( P < 0.0001). d Difference in liver weight between oncogene and oncogene + WSX1 groups ( P = 0.0088). e Comparison of overall survival ( P = 0.0217). f (Top) Summary of HCC mouse model in wild-type or WSX1 −/− C57BL/6J mice ( n = 6). (Bottom) Representative images of entire mouse livers in wild-type or WSX1 −/− mice. g Comparisons of H&E histology. h Comparisons of percentage of liver area containing preneoplastic/tumor lesions ( P = 0.0012). i Difference in liver weight between wild-type or WSX1 −/− mice ( P = 0.0328). j Comparisons of overall survival ( P = 0.0252). k Expression of WSX1 in mouse liver tissues in the vector, oncogene, and oncogene + WSX1 groups. Scale bars, 100 μm. All data and images are representative of 3 independent experiments. Quantitative data are presented as mean ± SD and analyzed by two-sided Student t test. The survival curves were analyzed by the Kaplan–Meier method, and the log-rank test was used to compare overall survival between groups. * P < 0.05, ** P < 0.01, **** P < 0.0001. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

doi: 10.1038/s41467-021-23864-9

Figure Lengend Snippet: a (Top) Summary of NRAS/AKT oncogene-derived spontaneous HCC mouse model in FVB/NJ mice ( n = 8). Arrowheads represent hydrodynamic injection of WSX1 every week. (Bottom) Representative images of entire mouse livers in the oncogene and oncogene + WSX1 groups. b Comparisons of hematoxylin and eosin (H&E) histology. c Comparisons of percentage of liver area containing preneoplastic/tumor lesions based on H&E results ( P < 0.0001). d Difference in liver weight between oncogene and oncogene + WSX1 groups ( P = 0.0088). e Comparison of overall survival ( P = 0.0217). f (Top) Summary of HCC mouse model in wild-type or WSX1 −/− C57BL/6J mice ( n = 6). (Bottom) Representative images of entire mouse livers in wild-type or WSX1 −/− mice. g Comparisons of H&E histology. h Comparisons of percentage of liver area containing preneoplastic/tumor lesions ( P = 0.0012). i Difference in liver weight between wild-type or WSX1 −/− mice ( P = 0.0328). j Comparisons of overall survival ( P = 0.0252). k Expression of WSX1 in mouse liver tissues in the vector, oncogene, and oncogene + WSX1 groups. Scale bars, 100 μm. All data and images are representative of 3 independent experiments. Quantitative data are presented as mean ± SD and analyzed by two-sided Student t test. The survival curves were analyzed by the Kaplan–Meier method, and the log-rank test was used to compare overall survival between groups. * P < 0.05, ** P < 0.01, **** P < 0.0001. Source data are provided as a Source Data file.

Techniques: Derivative Assay, Injection, Comparison, Expressing, Plasmid Preparation

Journal: Nature Communications

Article Title: WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

doi: 10.1038/s41467-021-23864-9

Figure Lengend Snippet: a t-distributed stochastic neighbor embedding (t-SNE) map derived from time-of-flight mass cytometry (CyTOF) analysis of intrahepatic immune cells obtained from the HCC mouse model in Fig. ( n = 4). Cells are colored by clusters identified by Rphenograph. Clusters were grouped by expression profile and manually assigned to 6 main cell subsets: T cells, B cells, NK cells, Mϕ, DCs, and other CD3 − cells. b The percentage of T, B, NK, Mϕ, DC, and other CD3 − cells among all intrahepatic immune cells ( n = 4). c The proportion of CD4 + , CD8 + , CD4 + CD8 + DP, and CD4 − CD8 − DN T-cell subsets among total intrahepatic T cells ( n = 4). d t-SNE map of intrahepatic T cells derived from CyTOF analysis. Rphenograph identified 13 T-cell subsets based on expression profiles of 28 markers. e Heatmap showing expression of 28 T-cell panel markers in 13 T-cell clusters. f Differences in the proportion of 2 CD4 + (T2 and T10), 7 CD8 + (T3, T5, T7, T8, T9, T11, T12), 3 DP (T1, T4, T6), and 1 DN (T13) T-cell clusters among total intrahepatic T cells ( n = 4). WSX1 reduced the proportion of T1 ( P = 0.0114), T5 ( P = 0.0126) and T11 ( P = 0.0216), while increased the proportion of T6 ( P = 0.0003), T9 ( P = 0.0016) and T13 subsets ( P = 0.0453). All data are representative of 2 independent experiments. Quantitative data are presented as mean ± SD and analyzed by two-sided Student t test. * P < 0.05, ** P < 0.01, *** P < 0.001. NK cells natural killer cells, Mϕ macrophages, DCs dendritic cells, DP double positive, DN double negative. Source data are provided as a Source Data file.

Techniques: Derivative Assay, Mass Cytometry, Expressing

Depletion antibodies against CD8 + T (α-CD8), CD4 + T (α-CD4), and NK (α-NK) cells were used for immune-cell depletion in the spontaneous HCC mouse model. a Efficiency of in vivo immune-cell depletion was validated by flow cytometry. The gating strategy for sorting CD8 + T-cells, CD4 + T-cells, and NK cells is shown in the supplementary Fig. . b Effect of WSX1 on tumor growth with or without in vivo immune-cell depletion ( n = 5). Red arrowheads represent WSX1 injection once a week. Green arrowheads represent injection of the indicated antibodies 3 times a week. c Depletion of CD8 + T-cells impaired WSX1-mediated inhibition of HCC formation ( P = 0.0002). d Depletion of CD8 + T-cells decreased the WSX1-induced survival extension (HR = 7.078, P = 0.0338). All data and images are representative of 2 independent experiments. Quantitative data are presented as mean ± SD and analyzed by One-way ANOVA analysis. Tukey-Kramer multiple comparison tests were used for pairwise comparisons in the ANOVA analysis. The survival curves were analyzed by the Kaplan–Meier method, and the log-rank test was used to compare overall survival between groups. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, *** P < 0.001. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

doi: 10.1038/s41467-021-23864-9

Figure Lengend Snippet: Depletion antibodies against CD8 + T (α-CD8), CD4 + T (α-CD4), and NK (α-NK) cells were used for immune-cell depletion in the spontaneous HCC mouse model. a Efficiency of in vivo immune-cell depletion was validated by flow cytometry. The gating strategy for sorting CD8 + T-cells, CD4 + T-cells, and NK cells is shown in the supplementary Fig. . b Effect of WSX1 on tumor growth with or without in vivo immune-cell depletion ( n = 5). Red arrowheads represent WSX1 injection once a week. Green arrowheads represent injection of the indicated antibodies 3 times a week. c Depletion of CD8 + T-cells impaired WSX1-mediated inhibition of HCC formation ( P = 0.0002). d Depletion of CD8 + T-cells decreased the WSX1-induced survival extension (HR = 7.078, P = 0.0338). All data and images are representative of 2 independent experiments. Quantitative data are presented as mean ± SD and analyzed by One-way ANOVA analysis. Tukey-Kramer multiple comparison tests were used for pairwise comparisons in the ANOVA analysis. The survival curves were analyzed by the Kaplan–Meier method, and the log-rank test was used to compare overall survival between groups. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, *** P < 0.001. Source data are provided as a Source Data file.

Techniques: In Vivo, Flow Cytometry, Injection, Inhibition, Comparison

a Protein levels of WSX1, FLAG, and PD-L1 analyzed by Western blotting. HCC cell lines SNU449 and SNU475 were transfected with plasmid DNA encoding WSX1-FLAG (449 WSX1 and 475 WSX1 ) or with vector plasmids. b Effect of WSX1 overexpression on cell surface PD-L1 expression analyzed by flow cytometry. WSX1 overexpression reduced the proportion of PD-L1 + HCC cells in both SNU449 ( n = 4 independent experiments, P < 0.0001) and SNU475 cells ( P = 0.0002). c Immunoblotting analysis of protein levels of WSX1 and PD-L1 in SNU398 cells. CRISPR/Cas9 guiding RNAs against human WSX1 (crWSX1) were used for WSX1 knockdown, and nontargeting crRNAs were added as control (crCtrl). d WSX1 knockdown increased the proportion of PD-L1 + HCC cells in SNU398 cells ( n = 4 independent experiments, P = 0.0028). e t-SNE map derived from CyTOF analysis of mouse hepatocytes obtained from the HCC mouse model in Fig. . Cells were color coded by the intensity of the expression levels of PD-L1 and WSX1. f Difference in the proportions of PD-L1 + ( n = 4 mice, P = 0.0012) and WSX1 + mouse hepatocytes ( P = 0.0002) based on CyTOF analysis. Data shown are representative of 2 independent experiments. g Immunoblotting analysis of PD-L1 protein levels in mouse liver lysates (C1–C3 represent independent samples from “oncogene” group, T1–T3 are independent samples from “oncogene + WSX1” group). All images shown are representative of 3 independent experiments. Quantitative data are presented as mean ± SD and analyzed by two-sided Student t test. ** P < 0.01, *** P < 0.001, **** P < 0.0001. The gating strategy for sorting PD-L1 + HCC cells is shown in Supplementary Fig. . Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

doi: 10.1038/s41467-021-23864-9

Figure Lengend Snippet: a Protein levels of WSX1, FLAG, and PD-L1 analyzed by Western blotting. HCC cell lines SNU449 and SNU475 were transfected with plasmid DNA encoding WSX1-FLAG (449 WSX1 and 475 WSX1 ) or with vector plasmids. b Effect of WSX1 overexpression on cell surface PD-L1 expression analyzed by flow cytometry. WSX1 overexpression reduced the proportion of PD-L1 + HCC cells in both SNU449 ( n = 4 independent experiments, P < 0.0001) and SNU475 cells ( P = 0.0002). c Immunoblotting analysis of protein levels of WSX1 and PD-L1 in SNU398 cells. CRISPR/Cas9 guiding RNAs against human WSX1 (crWSX1) were used for WSX1 knockdown, and nontargeting crRNAs were added as control (crCtrl). d WSX1 knockdown increased the proportion of PD-L1 + HCC cells in SNU398 cells ( n = 4 independent experiments, P = 0.0028). e t-SNE map derived from CyTOF analysis of mouse hepatocytes obtained from the HCC mouse model in Fig. . Cells were color coded by the intensity of the expression levels of PD-L1 and WSX1. f Difference in the proportions of PD-L1 + ( n = 4 mice, P = 0.0012) and WSX1 + mouse hepatocytes ( P = 0.0002) based on CyTOF analysis. Data shown are representative of 2 independent experiments. g Immunoblotting analysis of PD-L1 protein levels in mouse liver lysates (C1–C3 represent independent samples from “oncogene” group, T1–T3 are independent samples from “oncogene + WSX1” group). All images shown are representative of 3 independent experiments. Quantitative data are presented as mean ± SD and analyzed by two-sided Student t test. ** P < 0.01, *** P < 0.001, **** P < 0.0001. The gating strategy for sorting PD-L1 + HCC cells is shown in Supplementary Fig. . Source data are provided as a Source Data file.

Techniques: Western Blot, Transfection, Plasmid Preparation, Over Expression, Expressing, Flow Cytometry, CRISPR, Knockdown, Control, Derivative Assay

a qRT-PCR assay revealed the influence of WSX1 on PD-L1 mRNA expression level ( n = 3 independent experiments). b Influence of WSX1 on the expression of exogenous PD-L1-FLAG. SNU449 and SNU475 cells were transfected with plasmid DNA encoding PD-L1-FLAG with or without WSX1 co-transfection and analyzed by Western blotting. c Immunoblot analysis of PD-L1 protein levels after treatment with proteasome inhibitor MG132 for 12 h. d Effect of MG132 on cell surface PD-L1 expression examined by flow cytometry. MG132 inhibited WSX1-mediated PD-L1 reduction in both SNU449 ( n = 5 independent experiments, P = 0.0027) and SNU475 cells ( P = 0.0362). e Influence of WSX1 on PD-L1 ubiquitination. Cells were pretreated with MG132 for 12 h, and cellular PD-L1 protein was pulled down by specific PD-L1 antibodies. PD-L1 ubiquitination was analyzed by anti-ubiquitin antibodies. f Impact of WSX1 on half-life of PD-L1 protein in HCC cells. HCC cells were treated with 25 mM CHX for 0, 4, 8, and 12 h, and cell lysates were collected separately and analyzed for PD-L1 protein levels. g Influence of WSX1 on protein levels of p-GSK3β Ser9 , total GSK3β, p-β-catenin Ser33/Ser37/Thr41 , and total β-catenin. β-catenin was directly phosphorylated by GSK3β at Ser33/Ser37/Thr41, and the level of p-β-catenin Ser33/Ser37/Thr41 indirectly reflects GSK3β activity. h Influence of GSK3β inhibitor LiCl or GSK3β knockdown on PD-L1 expression. Cell surface PD-L1 expression on WSX1-overexpressing 449 WSX1 and 475 WSX1 cells was analyzed by flow cytometry after treatment of LiCl or transfection of GSK3β shRNAs for 48 h. i Statistical analysis results showing that both LiCl treatment ( P = 0.0135 in 449 WSX1 and P = 0.0052 in 475 WSX1 ) and GSK3β knockdown ( P = 0.0020 in 449 WSX1 and P = 0.0015 in 475 WSX1 ) increased the proportion of PD-L1 + HCC cells ( n = 5 independent experiments). j Schematic of site-directed mutation of the consensus motif on PD-L1-NP (S176A, T180A, and S184A), which could not be phosphorylated by GSK3β. k SNU449 and SNU475 cells transfected with PD-L1-wild type (WT) or PD-L1-NP (mutated) alone or co-transfected with WSX1. Alterations in cell surface PD-L1 expression levels were determined by flow cytometry. l Quantification of PD-L1 MFI ratio. Site-directed mutation in PD-L1-NP impaired WSX1-mediated PD-L1 downregulation in both SNU449 ( n = 3 independent experiments, P = 0.0066 compared to PD-L1-WT) and SNU475 cells ( P = 0.0004 compared to PD-L1-WT). Quantitative data are presented as mean ± SD and analyzed by one-way ANOVA or Student t test. Tukey-Kramer multiple comparison test was used for pairwise comparisons in the ANOVA analysis. Unless otherwise noted, data and images shown are representative of 3 independent experiments. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, *** P < 0.001. CHX cycloheximide, SP signal peptide, TM transmembrane domain, ECD extracellular domain, ICD intracellular domain, MFI mean fluorescence intensity. The gating strategy for sorting PD-L1 + HCC cells is shown in Supplementary Fig. . Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

doi: 10.1038/s41467-021-23864-9

Figure Lengend Snippet: a qRT-PCR assay revealed the influence of WSX1 on PD-L1 mRNA expression level ( n = 3 independent experiments). b Influence of WSX1 on the expression of exogenous PD-L1-FLAG. SNU449 and SNU475 cells were transfected with plasmid DNA encoding PD-L1-FLAG with or without WSX1 co-transfection and analyzed by Western blotting. c Immunoblot analysis of PD-L1 protein levels after treatment with proteasome inhibitor MG132 for 12 h. d Effect of MG132 on cell surface PD-L1 expression examined by flow cytometry. MG132 inhibited WSX1-mediated PD-L1 reduction in both SNU449 ( n = 5 independent experiments, P = 0.0027) and SNU475 cells ( P = 0.0362). e Influence of WSX1 on PD-L1 ubiquitination. Cells were pretreated with MG132 for 12 h, and cellular PD-L1 protein was pulled down by specific PD-L1 antibodies. PD-L1 ubiquitination was analyzed by anti-ubiquitin antibodies. f Impact of WSX1 on half-life of PD-L1 protein in HCC cells. HCC cells were treated with 25 mM CHX for 0, 4, 8, and 12 h, and cell lysates were collected separately and analyzed for PD-L1 protein levels. g Influence of WSX1 on protein levels of p-GSK3β Ser9 , total GSK3β, p-β-catenin Ser33/Ser37/Thr41 , and total β-catenin. β-catenin was directly phosphorylated by GSK3β at Ser33/Ser37/Thr41, and the level of p-β-catenin Ser33/Ser37/Thr41 indirectly reflects GSK3β activity. h Influence of GSK3β inhibitor LiCl or GSK3β knockdown on PD-L1 expression. Cell surface PD-L1 expression on WSX1-overexpressing 449 WSX1 and 475 WSX1 cells was analyzed by flow cytometry after treatment of LiCl or transfection of GSK3β shRNAs for 48 h. i Statistical analysis results showing that both LiCl treatment ( P = 0.0135 in 449 WSX1 and P = 0.0052 in 475 WSX1 ) and GSK3β knockdown ( P = 0.0020 in 449 WSX1 and P = 0.0015 in 475 WSX1 ) increased the proportion of PD-L1 + HCC cells ( n = 5 independent experiments). j Schematic of site-directed mutation of the consensus motif on PD-L1-NP (S176A, T180A, and S184A), which could not be phosphorylated by GSK3β. k SNU449 and SNU475 cells transfected with PD-L1-wild type (WT) or PD-L1-NP (mutated) alone or co-transfected with WSX1. Alterations in cell surface PD-L1 expression levels were determined by flow cytometry. l Quantification of PD-L1 MFI ratio. Site-directed mutation in PD-L1-NP impaired WSX1-mediated PD-L1 downregulation in both SNU449 ( n = 3 independent experiments, P = 0.0066 compared to PD-L1-WT) and SNU475 cells ( P = 0.0004 compared to PD-L1-WT). Quantitative data are presented as mean ± SD and analyzed by one-way ANOVA or Student t test. Tukey-Kramer multiple comparison test was used for pairwise comparisons in the ANOVA analysis. Unless otherwise noted, data and images shown are representative of 3 independent experiments. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, *** P < 0.001. CHX cycloheximide, SP signal peptide, TM transmembrane domain, ECD extracellular domain, ICD intracellular domain, MFI mean fluorescence intensity. The gating strategy for sorting PD-L1 + HCC cells is shown in Supplementary Fig. . Source data are provided as a Source Data file.

Techniques: Quantitative RT-PCR, Expressing, Transfection, Plasmid Preparation, Cotransfection, Western Blot, Flow Cytometry, Ubiquitin Proteomics, Activity Assay, Knockdown, Mutagenesis, Comparison, Fluorescence

a Effect of WSX1 overexpression on protein levels of p-AKT Ser473 , AKT, p-TSC2 Thr1462 , and TSC2 in HCC cells determined by immunoblotting. TSC2 is directly phosphorylated at Thr1462 by AKT; thus p-TSC2 Thr1462 levels indirectly reflect AKT activity. b Impact of AKT reactivation on WSX1-mediated PD-L1 downregulation detected by flow cytometry. SNU449 and SNU475 cells were transfected with WSX1 alone or co-transfected with membrane-bound myr-AKT. Statistical analysis results are shown on the right ( n = 5 independent experiments, P < 0.0001 in both SNU449 and SNU475 cells). c Impact of myr-AKT transfection on protein levels of p-AKT Ser473 , total AKT, and PD-L1 in 449 WSX1 and 475 WSX1 cells. d Immunoblotting analysis of expression of WSX1, PD-L1, and p-AKT Ser473 in whole liver lysates obtained from FVB/NJ mice injected with NRAS/AKT oncogenes with or without WSX1 (left, C1–C4 represent independent samples from “oncogene” group, T1–T4 are independent samples from “oncogene + WSX1” group). Statistical analysis of correlations of WSX1 with PD-L1 and p-AKT Ser473 expression in mouse livers (right). e Effect of WSX1 on expression of PTEN, PI3K-p85, PI3K-p110α, and PI3K-p110δ. f Impact of PIK3CD overexpression on WSX1-mediated PD-L1 reduction (left). PIK3CD encodes PI3K-p110δ, which is the key component of PI3Kδ. Reintroduction of PIK3CD impaired WSX1-induced PD-L1 reduction in both SNU449 ( n = 5 independent experiments, P = 0.0001) and SNU475 cells ( P = 0.0013). g Effect of WSX1 on PIK3CD mRNA levels in SNU449 ( n = 3 independent experiments P = 0.0139) and SNU475 HCC cells ( P = 0.0006). h A proposed model illustrating that WSX1 facilitates antitumor immune surveillance through inhibiting the PI3Kδ/AKT/GSK3β/PD-L1 signaling pathway. Under physiological conditions, highly expressed WSX1 in hepatocytes transcriptionally downregulates PIK3δ, thereby reducing AKT activation and subsequently liberating GSK3β kinase activity from inhibition by AKT, leading to boosted GSK3β-mediated PD-L1 degradation. Without excessive PD-L1 expression on tumor cells, effector CD8 + T cells maximize their killing effect, resulting in inhibition of HCC development (Left). Otherwise, lack of WSX1 results in uncontrolled neoplastic PD-L1 expression and, ultimately, tumor immune evasion (Right). i Schematic diagram of the interactions among WSX1, PI3Kδ, AKT, GSK3β, and PD-L1. Quantitative data are presented as mean ± SD and were analyzed by one-way ANOVA or Student t test. Tukey-Kramer multiple comparison test was used for pairwise comparisons in the ANOVA analysis. Correlation analyses were performed by Pearson correlation test. Unless otherwise noted, data and images shown are representative of 3 independent experiments. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, *** P < 0.001. myr-AKT myristoylated AKT. The gating strategy for sorting PD-L1 + HCC cells is shown in supplementary Fig. . Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression

doi: 10.1038/s41467-021-23864-9

Figure Lengend Snippet: a Effect of WSX1 overexpression on protein levels of p-AKT Ser473 , AKT, p-TSC2 Thr1462 , and TSC2 in HCC cells determined by immunoblotting. TSC2 is directly phosphorylated at Thr1462 by AKT; thus p-TSC2 Thr1462 levels indirectly reflect AKT activity. b Impact of AKT reactivation on WSX1-mediated PD-L1 downregulation detected by flow cytometry. SNU449 and SNU475 cells were transfected with WSX1 alone or co-transfected with membrane-bound myr-AKT. Statistical analysis results are shown on the right ( n = 5 independent experiments, P < 0.0001 in both SNU449 and SNU475 cells). c Impact of myr-AKT transfection on protein levels of p-AKT Ser473 , total AKT, and PD-L1 in 449 WSX1 and 475 WSX1 cells. d Immunoblotting analysis of expression of WSX1, PD-L1, and p-AKT Ser473 in whole liver lysates obtained from FVB/NJ mice injected with NRAS/AKT oncogenes with or without WSX1 (left, C1–C4 represent independent samples from “oncogene” group, T1–T4 are independent samples from “oncogene + WSX1” group). Statistical analysis of correlations of WSX1 with PD-L1 and p-AKT Ser473 expression in mouse livers (right). e Effect of WSX1 on expression of PTEN, PI3K-p85, PI3K-p110α, and PI3K-p110δ. f Impact of PIK3CD overexpression on WSX1-mediated PD-L1 reduction (left). PIK3CD encodes PI3K-p110δ, which is the key component of PI3Kδ. Reintroduction of PIK3CD impaired WSX1-induced PD-L1 reduction in both SNU449 ( n = 5 independent experiments, P = 0.0001) and SNU475 cells ( P = 0.0013). g Effect of WSX1 on PIK3CD mRNA levels in SNU449 ( n = 3 independent experiments P = 0.0139) and SNU475 HCC cells ( P = 0.0006). h A proposed model illustrating that WSX1 facilitates antitumor immune surveillance through inhibiting the PI3Kδ/AKT/GSK3β/PD-L1 signaling pathway. Under physiological conditions, highly expressed WSX1 in hepatocytes transcriptionally downregulates PIK3δ, thereby reducing AKT activation and subsequently liberating GSK3β kinase activity from inhibition by AKT, leading to boosted GSK3β-mediated PD-L1 degradation. Without excessive PD-L1 expression on tumor cells, effector CD8 + T cells maximize their killing effect, resulting in inhibition of HCC development (Left). Otherwise, lack of WSX1 results in uncontrolled neoplastic PD-L1 expression and, ultimately, tumor immune evasion (Right). i Schematic diagram of the interactions among WSX1, PI3Kδ, AKT, GSK3β, and PD-L1. Quantitative data are presented as mean ± SD and were analyzed by one-way ANOVA or Student t test. Tukey-Kramer multiple comparison test was used for pairwise comparisons in the ANOVA analysis. Correlation analyses were performed by Pearson correlation test. Unless otherwise noted, data and images shown are representative of 3 independent experiments. All statistical tests were two-sided. * P < 0.05, ** P < 0.01, *** P < 0.001. myr-AKT myristoylated AKT. The gating strategy for sorting PD-L1 + HCC cells is shown in supplementary Fig. . Source data are provided as a Source Data file.

Techniques: Over Expression, Western Blot, Activity Assay, Flow Cytometry, Transfection, Membrane, Expressing, Injection, Activation Assay, Inhibition, Comparison

Review

Structured Review

Images

1) Product Images from "Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner"

Similar Products

Image Search Results